The GTB‐3550 TriKE (CD16/IL‐15/CD33), showing promising anti‐tumour efficacy in early studies, led to the launch of a phase I/II clinical trial for treating refractory AML and high‐risk MDS. This evidence concerns the gene FCGR3A and neoplasm.